ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT™) in the country, which addresses aging concerns caused by loss of structural support in the mid-face.

瑞士祖格——（商业新闻短讯）——高德玛（SWX:GALD）今天宣布在中国推出其透明质酸注射填充剂Restylane®VOLYME™。该公司还将在国内推出其补充成型整体个性化治疗（HIT™），以解决因面部中部结构支撑丧失而引起的衰老问题。

The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs in China. In the past decade, the growth of China’s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.1.

这些针对中面部区域的目标解决方案的可用性证明了高德玛致力于满足中国患者和注射器的需求。在过去的十年中，中国美容医学市场的增长速度已经超过了全球市场；由于市场渗透率相对较低，未来的增长潜力仍然很大。

Developed using Galderma’s proprietary OBT™* gel technology, Restylane® VOLYME™ is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.2-3 Hyaluronic acid fillers are often patients’ first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.4 In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.1.

使用Galderma专有的OBT™*凝胶技术开发的Restylane®VOLYME™可通过注射到皮肤的皮下至骨膜上层来纠正面部中部容积不足和/或面部中部轮廓不足。2-3透明质酸填充剂通常是患者面部中部增大的首选，并已被证明可提供高患者满意度和持久效果。4在中国，透明质酸填充剂是十大最畅销的美学产品之一。

“We are delighted to deliver Galderma’s innovative aesthetics solutions in China with the support of our research and development teams, as well as local partners and regulatory authorities. As the Chinese market continues to expand, we look forward to working closely with all stakeholders to deliver our full, premium range of aesthetics products to meet the varied and individual needs of patients and injectors.”.

“我们很高兴在我们的研发团队、当地合作伙伴和监管机构的支持下，在中国提供高德玛创新美学解决方案。随着中国市场的不断扩大，我们期待着与所有利益相关者密切合作，提供全套优质美学产品，以满足患者和注射器的多样化和个性化需求。”。

GERRY MUHLE

GERRY MUHLE

HEAD OF GLOBAL PRODUCT STRATEGY

全球产品战略负责人

GALDERMA

加尔德玛

Developed with a global community of injectors, the Shape Up HIT™ is the latest of Galderma’s HITs™ to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront..

Shape Up HIT™是Galderma HITs™在中国推出的最新产品，由全球注射器社区共同开发，旨在创造一种通用语言，促进患者和从业者之间的双向对话，以符合患者的优先事项，并将满意度保持在最前沿。。

'Aesthetic plastic surgery is an artistic creation under medical

“美容整形手术是医学下的艺术创造

constraints, embodying a holistic and individualized approach. Facial expressions are controlled by 42 muscles which convey emotions such as joy, anger, sorrow, and happiness. These muscles are also involved in language, chewing, and other activities. The appearance of the mid-face is crucial in interpersonal communication.

约束，体现整体和个性化的方法。面部表情由42块肌肉控制，这些肌肉传达喜悦、愤怒、悲伤和幸福等情绪。这些肌肉也参与语言、咀嚼和其他活动。中脸的出现在人际交往中至关重要。

Together, Restylane® VOLYME™ and the Shape Up HIT™ enable patients to maintain their natural facial expressions while also supporting injectors to deliver a youthful and long-lasting aesthetic effect.'.

Restylane®VOLYME™和Shape-Up-HIT™使患者能够保持自然的面部表情，同时也支持注射器提供年轻持久的美学效果。”。

PROFESSOR HAIYAN CUI

崔海燕教授

DIRECTOR OF THE INSTITUTE OF AESTHETIC PLASTIC SURGERY AND MEDICINE

美容整形医学研究所所长

TONGJI UNIVERSITY

同济大学

DIRECTOR OF THE PLASTIC & COSMETIC SURGERY DEPARTMENT

整形美容外科主任

TONGJI HOSPITAL OF TONGJI UNIVERSITY

同济大学同济医院

HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane® portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. The Balanced Profile HIT™ was Galderma’s first HIT™ to be introduced in China in 2023, providing a framework for practitioners to conduct a full objective facial assessment for the patient and help bring balance to their profile.

HIT™是一种个性化治疗方法，使注射器能够利用其专业知识和著名的Galderma Restylane®产品组合来优化美学效果，同时优先考虑患者满意度。Balanced Profile HIT™是高德玛于2023年在中国推出的第一款HIT™产品，为从业者提供了一个框架，可以对患者进行全面客观的面部评估，并有助于平衡患者的面部轮廓。

HIT™ naturally springboards from Galderma’s AART™ (Assessment, Anatomy, Range, Treatment) methodology for a new generation of individualized aesthetics..

HIT™是Galderma的AART™（评估、解剖、范围、治疗）方法论为新一代个性化美学提供的天然跳板。。

Restylane® is the largest and most diverse range of individually engineered hyaluronic acid fillers on the market, approved in more than 80 countries and regions, and with over 65 million treatments administered worldwide.5-8

Restylane®是市场上最大、种类最多的单独工程透明质酸填充剂，已在80多个国家和地区获得批准，在全球范围内进行了6500多万次治疗。5-8

About Galderma

关于Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

Galderma（SIX：GALD）是新兴的纯皮肤病学类别领导者，分布在大约90个国家。我们通过注射美学、皮肤科皮肤护理和治疗性皮肤病学，提供创新、科学的优质旗舰品牌和服务组合，涵盖快速增长的皮肤病学市场的所有领域。

Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story.

自1981年成立以来，我们一直专注于人体最大的器官-皮肤-与医疗保健专业人员合作，以优异的效果满足个人消费者和患者的需求。因为我们了解我们所处的皮肤塑造了我们的生活，所以我们正在为每一个皮肤故事推进皮肤病学。